Page 2 - Analytical Solutions News Today

Revvity (NYSE:RVTY – Get Free Report) and Illumina (NASDAQ:ILMN – Get Free Report) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Earnings and Valuation This table compares Revvity and Illumina’s […]

Revvity (NYSE:RVTY – Get Free Report) was upgraded by equities researchers at Evercore ISI from an “in-line” rating to an “outperform” rating in a research report issued on Thursday, Briefing.com reports. The firm currently has a $125.00 price target on the stock, up from their prior price target of $88.00. Evercore ISI’s price target would […]

Revvity (NYSE:RVTY – Get Free Report) and Many Bright Ideas Technologies (OTCMKTS:MBGNF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability. Earnings and Valuation This table compares Revvity […]

Wells Fargo & Company began coverage on shares of Revvity (NYSE:RVTY – Free Report) in a research report report published on Tuesday morning, Marketbeat reports. The brokerage issued an equal weight rating and a $95.00 target price on the stock. A number of other equities analysts also recently commented on the stock. Raymond James reduced […]

Revvity (NYSE:RVTY – Get Free Report) and Cue Health (NASDAQ:HLTH – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation. Institutional & Insider Ownership 82.6% of Revvity shares are […]

Testa Analytical has launched a new 21CFR Part 11 compliance software designed for its NanoBrook particle sizing and zeta potential instrumentation. Click to read more...

10x Genomics (NASDAQ:TXG – Get Free Report) and Revvity (NYSE:RVTY – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings. Risk & Volatility 10x Genomics has a beta of […]

Revvity (NYSE:RVTY – Get Free Report) had its price target lowered by The Goldman Sachs Group from $120.00 to $105.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 27.21% from the […]

Revvity (NYSE:RVTY – Get Free Report) issued an update on its FY23 earnings guidance on Monday morning. The company provided earnings per share guidance of $4.53-4.57 for the period, compared to the consensus earnings per share estimate of $4.78. The company issued revenue guidance of $2.72-2.74 billion, compared to the consensus revenue estimate of $2.83 […]

Revvity, Inc. (NYSE:RVTY – Get Free Report) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among […]